Human MAIT cells inhibit alloreactive T cell responses and protect against acute graft-versus-host disease
JCI Insight · 2024
DOI: 10.1172/jci.insight.166310 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2024. Verfasst von Nana Talvard-Balland und 12 weiteren Autor:innen. Beteiligte Einrichtung: INSERM UMR-976 HIPI, Saint Louis Research Institute, Université Paris Cité, Paris, France. Hauptthemen laut MEDLINE: Mucosal-Associated Invariant T Cells, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Institut National Du Cancer.
Abstract (Originalsprache)
Adoptive transfer of immunoregulatory cells can prevent or ameliorate graft-versus-host disease (GVHD), which remains the main cause of nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Mucosal-associated invariant T (MAIT) cells were recently associated with tissue repair capacities and with lower rates of GVHD in humans. Here, we analyzed the immunosuppressive effect of MAIT cells in an in vitro model of alloreactivity and explored their adoptive transfer in a preclinical xenogeneic GVHD model. We found that MAIT cells, whether freshly purified or short-term expanded, dose-dependently inhibited proliferation and activation of alloreactive T cells. In immunodeficient mice injected with human PBMCs, MAIT cells greatly delayed GVHD onset and decreased severity when transferred early after PBMC injection but could also control ongoing GVHD when transferred at delayed time points. This effect was associated with decreased proliferation and effector function of human T cells infiltrating tissues of diseased mice and was correlated with lower circulating IFN-γ and TNF-α levels and increased IL-10 levels. MAIT cells acted partly in a contact-dependent manner, which likely required direct interaction of their T cell receptor with MHC class I–related molecule (MR1) induced on host-reactive T cells. These results support the setup of clinical trials using MAIT cells as universal therapeutic tools to control severe GVHD or mucosal inflammatory disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM UMR-976 HIPI, Saint Louis Research Institute, Université Paris Cité, Paris, France.
- Institut Curie, Université PSL, INSERM U932, Immunity and Cancer, Paris, France.
- Université Paris Cité, INSERM, CNRS, UMS Saint-Louis (US53/UAR2030), Paris, France.
- Institut Curie, Université PSL, CNRS UMR3666, INSERM U1143, Paris, France.
- Hematology Transplantation, Hôpital Saint-Louis, Assistance Publique-Hôpitaux de Paris (AP-HP), Université Paris Cité, Paris, France.
- Clinical Immunology Laboratory, Institut Curie, Paris, France.
Förderung
- Institut National Du Cancer
Zitieren
APA
Talvard-Balland, N., Lambert, M., Chevalier, M. F., Minet, N., Salou, M., Tourret, M., Bohineust, A., Milo, I., Parietti, V., Yvorra, T., Socié, G., Lantz, O., & Caillat-Zucman, S. (2024). Human MAIT cells inhibit alloreactive T cell responses and protect against acute graft-versus-host disease. JCI Insight. https://doi.org/10.1172/jci.insight.166310
Vancouver
Talvard-Balland N, Lambert M, Chevalier MF, Minet N, Salou M, Tourret M, et al. Human MAIT cells inhibit alloreactive T cell responses and protect against acute graft-versus-host disease. JCI Insight. 2024. doi:10.1172/jci.insight.166310
BibTeX
@article{TalvardBalland2024,
author = {Talvard-Balland, Nana and Lambert, Marion and Chevalier, Mathieu F and Minet, Norbert and Salou, Marion and Tourret, Marie and Bohineust, Armelle and Milo, Idan and Parietti, Véronique and Yvorra, Thomas and Socié, Gérard and Lantz, Olivier and Caillat-Zucman, Sophie},
title = {Human MAIT cells inhibit alloreactive T cell responses and protect against acute graft-versus-host disease},
journal = {JCI Insight},
year = {2024},
doi = {10.1172/jci.insight.166310}
}
EUVIMED